C62

C62 is an investigational drug with two primary applications identified in the provided context. It functions as a potent neutralizing antibody specifically targeting the receptor binding domain S1B of the Porcine Epidemic Diarrhea Virus (PEDV)-S1 protein, demonstrating efficacy in inhibiting viral attachment and mitigating PEDV infection in piglets. Additionally, C62 is a key component of HIV-1 vaccine candidates, such as C62-M4 and C1C62-M3M4, which are being evaluated for their safety and immunogenicity in individuals with HIV-1 suppressed on antiretroviral therapy, aiming to enhance the immune system's ability to clear HIV from cells.